We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.46 | -0.93% | 49.00 | 49.00 | 49.95 | 49.595 | 48.97 | 49.48 | 1,113,911 | 01:00:00 |
By Michael Dabaie
MyoKardia Inc. (MYOK) now anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of previous guidance of the second half of 2020.
Patient screening has closed for the Phase 3 EXPLORER-HCM study to assess mavacamten in treating patients with obstructive hypertrophic cardiomyopathy. Enrollment into the pivotal trial is expected to be completed by mid-August, MyoKardia said.
MyoKardia also said it re-acquired U.S. royalty rights to mavacamten and MYK-224 from Sanofi S.A. (SNY, SAN.FR). As consideration for the buyback of the U.S. royalty rights to these programs, MyoKardia is paying Sanofi $50 million upfront, with an additional $30 million payable by June 30, 2020.
MyoKardia shares were up 0.4% premarket to $50.00.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 18, 2019 09:14 ET (13:14 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions